Neurotop (Carbamazepine)

Carbamazepine blocks voltage‑gated sodium channels on neurons, preventing rapid depolarisation and repetitive firing. This stabilises hyperexcited neuronal membranes, thereby reducing abnormal electrical activity that leads to seizures, mood swings, and neuropathic pain.

The appropriate dose of Neurotop is determined individually by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and response to therapy. Dosage adjustments are made according to medical guidance.

Carbamazepine crosses the placenta and is excreted in breast milk. Its safety in pregnancy and lactation is not fully established, so clinicians weigh potential benefits against risks. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To request Neurotop, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as valproate or phenytoin, carbamazepine (Neurotop) is particularly effective for focal seizures and trigeminal neuralgia, but it may have a higher risk of skin reactions and drug interactions. Choice of therapy depends on seizure type, comorbidities, and individual tolerance.

Neurotop should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight and heat sources to maintain stability and potency throughout its shelf life.

Neurotop is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water; crushing or chewing is not recommended unless specifically instructed by a healthcare professional.

Serious risks include severe blood disorders such as agranulocytosis, life‑threatening skin reactions like Stevens‑Johnson syndrome, hepatic failure, and cardiac conduction abnormalities. Patients should report any signs of rash, fever, unexplained bruising, jaundice, or irregular heartbeat promptly.

Neurotop is contraindicated in individuals with known hypersensitivity to carbamazepine or related compounds, those with a history of bone marrow suppression, and patients with significant cardiac conduction disorders without appropriate monitoring. It should also be used with caution in patients with hepatic or renal impairment.